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The lack of standardization of methods to measure cardiac
markers for coronaria ischaemia, particularly troponin, led us to
perform an analytical evaluation of two new immunoassays to
quantify CK-MB mass and troponin I using the Dimension RxL
automatic analyser. The reliability and analytical intervals of the
methods were studied as well as reference values (0.010º
0.228mgl
º 1 for troponin I, 0.20º3.90mgl
º 1 for CK-MB mass)
and cuto¡ values (0.77mgl
º 1 for troponin I, 5mgl
º 1 for CK-MB
mass) established. The cuto¡ values were established from 37
patients with acute myocardial infarction and from 20 with
unstable angina. The absence of method cross-reactivity was
corroborated using myocardial, brain and skeletal muscle tissue.
Both methods were highly speci¢c and showed good reliability and
practicability in the diagnosis of coronaria ischaemia after 6h of
precordial pain.
Introduction
Only 10% of patients presenting in the emergency
department with maintained precordial pain show an
elevation in the ST segment of an electrocardiogram. In
acute coronary ischaemia processes other than infarction
with an elevated ST segment (non-Q infarction or with-
out a fall in the ST, unstable angina and unidenti® ed
ischaemia), the use of biochemical markers may be the
only criteria to diagnose myocardial necrosis and in some
cases to establish the prognosis.
For many years, the enzymatic pro® le (creatine kinase,
CK-MB isoenzyme activity, aspartate aminotransferase,
lactate dehydrogenase) has been the biochemical method
of choice i the diagnosis of acute myocardial infarction
(AMI). Indeed, the World Health Organization (WHO)
continues to use the catalytic CK-MB activity and
creatine kinase in the diagnosis of AMI [1].
In the 1990s, more sensitive and speci® c cardiac markers
have been developed to detect this diseases. A coronary
ischaemia marker must ful® l the following characteristics:
(1) a simple methodology providing rapid results 24 h a
day; (2) a high diagnostic sensitivity, specially during the
® rst 24h of the ischaemic process; and (3) diagnostic
speci® city as close to 100% as possible. The following
markers were used: serum myoglobin, CK-MB isoforms,
CK-MB protein concentration (CK-MB mass), and tro-
ponins I and T. Each marker has pros and cons with
respect to others and there is no consensus about the ideal
marker. Myoglobin is the earliest marker and is highly
sensitive in the diagnosis of the disease within 2h of
precordial pain [2, 3]. However, its diagnostic speci® city
is poor. The CK-MB isoforms are very early markers
with good sensitivity within 4± 6h of precordial pain with
relatively high speci® city [4]. However, the technology
used to perform this method is complicated [5] and
expensive [6]. Protein concentration of CK-MB has
markedly improved the analytical speci® city and sensi-
tivity of the activity of CK-MB methods [7, 8]. CK-MB
mass has a high diagnostic sensitivity 4± 6h after precor-
dial pain and remains increased for the ® rst 48h. The
cardiospeci® city of troponin [9] together with its wide
diagnostic window (elevations persist in plasma from
6± 12 h to 5± 10 days for troponin I and from 6± 12h to
5± 15 days for troponin T) have revolutionized the
diagnosis of coronary ischaemia in the last few years
[10± 13].
In the 2000s, the Joint Committee of the European
Society of Cardiology and the American College of
Cardiology established rede® ned criteria to classify
acute coronary syndromes [14] and they proposed tro-
ponin and CK-MB mass as biochemical markers of
myocardial necrosis. Recently, Apple and Wu [15] stated
that cardiac troponin is the best marker for diagnosis, risk
strati® cation and guidance of therapy in acute coronary
syndromes.
The correct choice of a cardiac marker according to the
time of evolution of the ischaemic process is, currently,
controversial, and the scienti® c societies are attempting
to protocolize this choice [16± 18]. The lack of method
standarization [19, 20], specially measuring troponin,
has made it diæ cult to compare the results and choose
the best method [21]. In fact, scienti® c societies are, at
present, elaborating primary [22] and reference materials
[23] for cardiac markers, with the aim of achieving the
transferability of results and establishing the diagnostic
limits to facilitate the clinical use of these markers. The
National Academy of Clinical Biochemistry (NACB) has
suggested that two cutoå values for the troponins be
used, one indicative of AMI and the other indicative of
cardiac injury [17]. Accurate discrimination between
minor myocardial injury versus analytical imprecision
requires high interassay precision at the low cutoå values.
Thus, the NACB has recommended a precision for
cardiac troponin assays of µ10% [17].
Therefore, each laboratory should evaluate its methods,
especially with troponin I, and establish its reference
ranges and cutoå values as well as the clinical sensitivity
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51and speci® city for the diå erent processes of acute cor-
onary ischaemia [21]. In the present study, we performed
an analytical evaluation of two new methods to measure
the protein concentration of CK-MB mass and cardiac
troponin I using the Dimension RxL automatic analyser
(Dade Behring, Newark, DE, USA).
Materials and methods
Patients
We investigated 37 patients with con® rmed AMI ad-
mitted to the coronary care unit (CCU). The de® nitive
diagnosis of AMI required, at least, two of the following
three clinical criteria proposed by the WHO [1]: typical
prolonged severe chest pain of > 20-min duration, the
evolution of abnormal Q waves or equivalents on serial
ECGs, and serial CK and CK-MB elevations with an
initial rise and subsequent fall peak. Twenty patients
with a clinical diagnosis compatible with unstable angina
were included in the study. Blood was withdrawn at
diå erent time intervals after precordal pain.
Reference values were calculated from 50 samples ob-
tained from apparently normal people free of cardiologi-
cal diseases sent to our laboratory for analytical control
before minor surgical interventions.
To study the cross-reactivity of the methods, samples of
myocardial, brain and skeletal muscle (biceps, quadri-
ceps) from a subject were obtained at autopsy 20h after
death. The patient had died in an accident. Ethical
permission for tissue donation was previously obtained.
Samples were frozen at ± 808C until their analyses.
Analytical methods
. Troponin I (cat. no. RF421; Dade Behring). The
immunoassay was based on the sandwich principle
with two monoclonal antibodies binding to a con-
jugate reagent composed with alkaline phosphatase.
The coloured ® nal product absorbed at 510nm.
. Protein concentration of CK-MB (CK-MB mass)
(cat. no. RF420; Dade Behring). The immunoassay
was based on the sandwich principle with a mono-
clonal antibody speci® c for MB isoenzyme and
another against the B subunit of creatine kinase.
The detection system is b-galactosidase.
. Catalitic activity of CK-MB (cat. no. DF31; Dade
Behring). The immunoinhibition method detected
the B subunit of creatine kinase.
. Creatine kinase activity (CK) (cat. no. DF29A;
Dade Behring).
The assays were carried out in an automatic analyser
Dimension RxL.
Analytical evaluation of the methods
The analytical intervals of the methods were evaluated
following the directions of the Socite ¨ Franc° aise de
Biologie Clinique [24]. To calculate the analytical inter-
val, nine standard aqueous solutions of troponin I
(cardiac troponin I calibrator; Dade Behring cat. no.
RC421B) ranging from 0.1 to 60mgl
± 1 and of CK-MB
(mass creatine kinase MB isoenzyme calibrator Dade
Behring cat. no. RC420) (1± 400mgl
± 1) were used. The
recommendations of the European Committee for Clin-
ical Laboratory Standards (ECCLS) were followed for
the study of the imprecision and inaccuracy of the
method [25]. Control serums of 0.34, 0.68, 2.42, 9.7
and 22.6 mgl
± 1 troponin I and 2, 4.9, 7.5, 15.1 and
42.6 mgl
± 1 CK-MB mass were used.
To determine the analytical recovery of the methods,
increasing the quantities of troponin I to CK-MB mass
were added to diå erent aliquots of sera pool. A total of
20, 30 and 40mgl
± 1 troponin I and 50, 100 and 200mgl
± 1
CK-MB mass were the standard aqueous solutions used.
The dilution eå ect was corrected by adding the same
volume of saline solution to unaltered samples.
The reference values of the methods were obtained
following the recommendations of the Panel of Experts
of the IFCC on reference values [26].
Tissue speci¢city of the methods
Cross-reactivity for CK-MB mass method was carried out
with homogenates from myocardial, brain and skeletal
muscle tissue. The crude extracts preparation was per-
formed following the previous protocol used for myocar-
dial tissue [27, 28]. Tissue was homogenized in 2 vols
50mmoll
± 1 Tris-HCl buå er, pH8.0, containing
2mmoll
± 1 2-mercaptoethanol with a Polytron ATA 20
TSM homogenizer (Kinematica Gmb, Littau, Switzer-
land). Homogenization was carried out in an ice bath at
48C for 45 min. After centrifugation of the homogenate
at 4000g for 15 min in a Beckman J2-21 centrifuge
(Beckman Instruments, Palo Alto, CA, USA), the super-
natant was collected and ® ltered. The protein concentra-
tion of CK-MB and the catalytical activity of total
creatine kinase were measured in the supernatant.
The cardiospeci® city of troponin was veri® ed using
myocardial and skeletal muscle (quadriceps, biceps)
tissue. Troponin I was measured in myo® brillar and
cytosolic fractions of these tissues. To separate these
fractions, the protocol of Katus et al. was applied [29].
The tissue was homogenized in a buå er (50mmoll
± 1
Tris-HCl, 2mmoll
± 1 EDTA, 0.05mmoll
± 1 dithiotreitol,
pH7.0) and stirred at 48C for 1h. The insoluble mol-
ecules were precipitated by ultracentrifugation for 1h at
100000g (48C). The pellet was washed and centrifuga-
tion was repeated. The troponins contained in the
myo® brillar fraction were extracted by homogenization
of the precipitate for 1h at 48C in a solution composed
by 0.4mol l
± 1 potassium chloride, 0.01moll
± 1 magnesium
chloride, 0.1 moll
± 1 potassium dihydrogen phosphate,
0.05 moll
± 1 potassium monohydrogen phosphate,
0.04 moll
± 1 sodium pyrophosphate, pH 7.0. The solubi-
lized troponin complex was separated from actomyosin
by centrifugation for 1h at 20000g at 48C. Troponin I
concentration was measured in the myo® brillar and
soluble fractions as well as in the myocardial and skeletal
muscle homogenates. The protein content was measured
by a pirogallol red method [30].
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The decision limits for the markers were obtained using
receiver operating characteristic (ROC) curves.
Statistical methods
Mean, SD and coeæ cient of variation for studying the
accuracy and imprecision were used. Analytical intervals
were determined by regression analyses. The Mann±
Whitney U-test was applied to establish the statistical
diå erences between groups. To calculate the reference
values of the method, the 2.5, 50 and 97.5 percentiles
were used. ROC curves were applied to obtain the cutoå
values. Con® dence intervals (95%) of sensitivities were
calculated non-parametrically. The À
2-test was used to
compare the percentages of sensitivity.
Results
Analytical interval of methods
The analytical interval for CK-MB mass ranged from 0.1
to 341 mgl
± 1. Figure 1 shows the linear regression of the
least-squares ( y ˆ 0:978x ‡ 0:24; r ˆ 0:999) established
among the theoretical values of the CK-MB standards
processed in triplicate over 3 consecutive days, and the
values found. The analytical interval for troponin I was
0.05± 50mgl
± 1 (® gure 2).
Imprecision and inaccuracy
Table 1 contains the variation coeæ cients for the tropo-
nin I method. The study of imprecision for the CK-MB
method is summarized in table 2. The percentages of
inaccuracy with respect to the theoretical value did not
exceed 10% (tables 3 and 4).
Analytical recovery study. Analytical recovery ranged from
98.7 to 102% for troponin I (table 5) and 98± 103% for
CK-MB mass (table 6).
Figure 1. Analytical interval for CK-MB mass. Reference line
(º) y= bx (b= 1). Regression line (.....) mean and 2 SD of
each point ( ). The means of the points found and their 2 SD
coincide with the reference line from 0.1 to 341mgl
º 1
Figure 2. Analytical interval for troponin I. Reference line (º)
y= bx (b= 1). Regression line (.....) mean and 2 SD of each
point ( ). The means of the points found and their 2 SD coincide
with the reference line from 0.05 to 50mgl
º 1.
Table 1. Imprecision of the troponin I method.
Concentration
of troponin I Within-run Between-run
(mgl
¡1) n CV (%) CV (%)
0.34 20 9.8 11.2
0.68 20 5.0 5.5
2.42 20 4.3 4.9
9.7 20 3.7 4.7
22.6 20 4.8 4.9
CV, coeæ cient of variation.
Table 2. Imprecision of the CK-MB mass method.
Concentration
of CK-MB mass Within-run Between-run
(mgl
¡1) n CV (%) CV (%)
2.0 20 9.5 11.8
4.0 20 4.9 5.0
7.5 20 3.1 4.0
15.1 20 4.5 6.7
42.6 20 4.7 4.8
CV, coeæ cient of variation.
Table 3. Inaccuracy of the troponin I method.
Theoretical Found
concentration concentration




0.34 20 0.325 74.4
9.7 20 10.15 4.6
22.6 20 23.2 2.6
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The reference values for the cardiac markers studied are
contained in table 7. Statistical diå erences between men
and women groups were not found for any marker:
troponin I (p > 0:05), CK-MB mass (p > 0:05), CK-
MB mass/total CK (p > 0:05). Thus, the reference values
were established in the total population.
Crossreactivity
The CK-MB mass method showed the absence of cross-
reactivity with CK-BB and CK-MM. CK-MB concen-
tration in myocardial extract was similar before and after
the addition of 1500 Ul
± 1 CK-BB from brain tissue or to
12000 Ul
± 1 CK-MM from skeletal muscle tissue (® gure
3). The absence of troponin I in skeletal muscle was
corroborated: the concentration of troponin I in biceps
and quadriceps was not detected (< 1% of the values
obtained in myocardial tissue). The troponin I concen-
tration in the myo® brillar fraction of cardiac tissue was
7.2mgg
± 1 protein and only 4% of total troponin content
was found in the soluble fraction (® gure 4).
Table 4. Inaccuracy of the CK-MB mass method.
Theoretical Found
concentration concentration




4.0 20 4.19 4.75
15.1 20 14.4 74.6
42.6 20 43.1 1.1
Table 5. Recovery study for troponin I.
Troponin I Theoretical troponin I Troponin I concentration Recovery
Serum pool (mmoll
¡1) added (mmoll
¡1) concentration (mmol l
¡1) found (mmol l
¡1) (%)
50 20 70 71 101
50 30 80 79 98.7
50 40 90 92 102
Table 6. Recovery study for CK-MB mass.






80 50 130 134 103
80 100 180 182 101
80 200 280 276 98
Figure 3. Tissue speci¢city for the CK-MB mass method. No
di¡erences were found between the CK-MB mass concentration of
the crude extract of myocardial tissue before and after adding
1500Ul
º 1of CK-BB (t= 0.12, p= 0.885) and 12 000Ul
º 1 of
CK-MM (t= 0.21, p= 0.771).
Table 7. Reference values.
Males Females Total
(n ˆ 42) (n ˆ 48) p (n ˆ 90)
Troponin I (mgl
¡1)
Range (p2.5, p97.5) 0.011± 0.227 0.010± 0.225 >0.05 0.010± 0.228
Mean (p50) 0.052 0.053 0.051
CK-MB mass (mgl
¡1)
Range (p2.5, p97.5) 0.21± 3.5 0.19± 4.0 >0.05 0.20± 3.90
Mean (p50) 0.911 0.890 0.900
CK-MB mass/CK (%)
Range (p2.5, p97.5) 0.38± 4.6 0.43± 4.9 >0.05 0.42± 4.82
Mean (p50) 1.5901 1.6002 4.6061
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ROC curves were applied to establish the diagnostic
decision limits of the methods. Table 8 shows the
percentages of sensitivity of troponin I for cardiac
markers in AMI using the cutoå values that established
(0.228 and 0.77mgl
± 1) and the cutoå value proposed by
the manufacturer (1.5mgl
± 1). In the early 6h of pre-
cordial pain, the sensitivity of troponin I, using the
reference value (0.228mgl
± 1) as a cutoå , was similar to
CK-MB mass (À2 ˆ 0:82, p > 0:05). However, the sensi-
tivities of troponin I using 0.77 and 1.5mgl
± 1 were lower
and signi® cantly diå erent than CK-MB mass (À2 ˆ 12,
p < 0:01; and À2 ˆ 34, p < 0:001, respectively). After 7h
of precordial pain, the sensitivity was reliable using any
cutoå value.
Table 9 contains the percentage of patients with unstable
angina and the increase of cardiac marker values. No
diå erences were found (p > 0:05) between the percen-
tages of sensitivity for troponin I using 0.228, 0.77 or
1.5mgl
± 1 as the cutoå . The sensitivity for CK-MB mass
was lower than troponin I (p < 0:05) to diagnose mini-
mum myocardial damage.
Discussion
The CK-MB mass method presented demonstrates good
analytical precision for concentrations with clinical
pathological signi® cance of the isoenzyme. However,
the variation coeæ cient within the normal limits is
> 10%, similar to that obtained by other authors for
other CK-MB mass methods [31]. At levels that were
slightly higher than our reference 0.34mgl
± 1, we found
analogically variation coeæ cients of 11.2% for the tro-
ponin I method. Nonetheless, > 0.68mgl
± 1, the impreci-
sion of the assay is < 5% with the variation coeæ cient
obtained being better than that reported for other
commercially available troponin tests [16, 21]. More-
Table 8. Sensitivites (95% con¢dence intervals) of biochemical markers in AMI at different hours after precordial pain and using
different cutoff values.
Troponin I Troponin I Troponin I CK-MB mass
Time interval (cutoå value (cutoå value (cutoå value (cutoå value





(%) (%) (%) (%)
2± 6 27 88 44.4 22.2 90
(75± 97) (27± 61) (14± 48) (77± 89)
7± 11 37 100 100 95 95.1
(91± 100) (91± 100) (82± 99) (80± 99)
12± 15 27 100 100 100 100
(91± 100) (91± 100) (91± 100) (91± 100)
16± 20 37 100 100 100 100
(91± 100) (91± 100) (91± 100) (91± 100)
21± 24 27 100 100 100 100
(91± 100) (91± 100) (91± 100) (91± 100)
Table 9. Increase of cardiac markers in patients with unstable angina. Percentage of sensitivity and 95% con¢dence intervals.
Time Troponin I Troponin I Troponin I CK-MB mass
interval after (cutoå value (cutoå value (cutoå value (cutoå value





(h) n (%) (%) (%) (%)
6+ /73 20 33 33 26 3
(20± 49) (20± 49) (10± 38) (0± 9)
14+/73 20 55 55 31 5
(37± 71) (37± 71) (9± 40) (1± 10)
22+/73 20 50 50 33 5
(32± 66) (32± 66) (18± 50) (0.5± 11)
Figure 4. Tissue speci¢city for the troponin I method. The lack of
cross-reactivity of troponin I with skeletal muscle is shown. No
troponin I concentrations in the crude extract of biceps and
quadriceps were detected. The troponin I concentration in the
myo¢brillar fraction of cardiac tissue was 7.2mgg
º 1 protein and
in the cytosolic fraction it was 0.3mgg
º 1 protein.
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markers is < 20 min, ful® lling the norms proposed by the
International Society of Enzymology [32] for cardiac
marker response time and is therefore compatible with
the results required in emergency department labora-
tories [17].
On the study of CK-MB cross-reactivity, we found that
contrary to methods analysing the catalytic activity of
CK-MB, the monoclonal antibody used in our CK-MB
mass method exclusively recognized the MB isoenzyme
and not the BB and MM isoenzymes of creatine kinase.
This method, therefore, improves the metrologic speci® -
city of the assay with regard to activity, although the
CK-MB mass is not 100% cardiospeci® c. The skeletal
muscle contains small, but signi® cant, quantities (1± 3%)
of the isoenzyme [33] and, thus, following massive
musculoskeletal lesions, this marker is elevated [34]. We
have also shown that the troponin I method evaluated
herein lacks cross-reactivity with human skeletal muscle
(biceps, quadriceps).
As a myo® brillar protein, troponin I may be present in
diå erent forms in blood (proteolytic fragments, intact
molecules, phosphorylated proteins or forming complexes
with other myo® brillar proteins). To do so, diå erent
recoveries of the respective antigen are obtained accord-
ing to the monoclonal antibody used. The currently
available commercial kits to measure troponin I diå er
in the antigenic speci® cities of the selected antibodies and
in the recovery of the fragments and complexes of
troponin I. This indicates the need for standardization
of the assays determining this marker and in the mean-
time each laboratory must establish their own reference
values and diagnostic decisions limits. For the method
evaluated, we have established reference values of be-
tween 0 and 0.28mgl
± 1, which are higher than those
proposed by the manufacturer (0± 0.05mgl
± 1). The diå er-
ences between the reference value of the diå erent assays
in the market may range to up to 10-fold [12, 21, 35, 36].
The choice of a cutoå point is one of the most widely
debated subjects [17, 37± 40]. From our results, it may be
seen that the cutoå point of 1.5mgl
± 1 proposed by the
manufacturer of the assay evaluated provides a diagnos-
tic sensitivity of only 22% for AMI during the ® rst 6h of
the ischaemic process. Moreover, the detection of the
small myocardial lesions with this cutoå point is lower
than that found when using the diagnostic cutoå values
we have established, although the diå erence is not
signi® cant. The best sensitivity for the diagnosis of AMI
is that obtained with 0.228mgl
± 1 (88% in the ® rst 6h of
the ischaemic process). However, the imprecision of the
method is > 10% at this concentration. Therefore,
although sensitivity is lost at 0.77mgl
± 1, since it is of
44.4% in the ® rst 6h of the pain, the reliability of the
method is much greater at these levels. Moreover,
according to our results, the sensitivity of the marker
for the small myocardial lesions is similar if either 0.228
or 0.77mgl
± 1 are used as the diagnostic cutoå value.
Nonetheless, our results agree with the criteria of many
authors [17, 18, 41] in that to obtain the true diagnostic
value of troponin I, > 6h of the ischaemic process must
go by. In fact, it is after 7h that our results show a
diagnostic sensitivity of 100% for AMI. The late appear-
ance of troponin in blood may be due to its profound
cellular localization since the 94% of troponin T and the
97% of troponin I are largely bound to the tropomyosin
complex and only the remaining 6 and 3%, respectively,
are found in the cytoplasm. In our study with cardiac
tissue, we only detected 4% of troponin I in the soluble
fraction in tissue. The wide diagnostic window of tropo-
nin (10± 15 days) may be due to its profound localization.
The cutoå value of 5mgl
± 1 for CK-MB mass, a method
which is more standardized than troponin, agrees with
that proposed by the manufacturer and some authors
working with other commercial kits [42, 43]. We have
demonstrated that the sensitivity of CK-MB mass for the
diagnosis of AMI during the ® rst 6h of precordial pain is
higher than troponin I using 0.77 and 1.5mgl
± 1 as the
cutoå values. Other authors [42, 44± 46] have had similar
results using other commercial kits. It must be taken into
account that although CK-MB has a greater molecular
mass than troponin, its intracellular localization is cyto-
plasmatic, thus favouring its release to the circulation. In
contrast, the possible localization of CK-MB in skeletal
muscle decreases the speci® city of the test for the diag-
nosis of coronary ischaemia.
In conclusion, the methods studied are highly speci® c,
and show good reliability and practicability for the
emergency diagnosis of acute coronary ischaemia. With
120 (l, sample results of the two cardiac markers may be
obtain in 16min. Both markers showed a reliable diag-
nostic sensitivity for acute myocardial infarction after 6h
of precordial pain. However, we proposed using 0.77
instead oå 1.5mgl
± 1 as the cutoå value for troponin I.
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